Company family
Cis Bio: medicine shortages
As of 2 Nov 2026, 4 Cis Bio products have a reported shortage across 4 countries, covering 1 medicines.
Products short4rank #348 of 464
Medicines1active ingredients
Countries4/16
New in 90 days4+4 vs market pace
Typical duration13 daysmedian so far
Manufacturing50%demand-driven 0%
Where
Which therapeutic classes
Why, compared with all companies
Manufacturing problemIncreased demandActive ingredient shortageDistribution or logisticsCommercial decision or withdrawalRegulatory or licensingOtherNot stated
Manufacturing problems point to the company's own supply chain; increased demand often follows a competitor's shortage or a demand shock.
Latest changes
All changes| Date | Country | Medicine | Change |
|---|---|---|---|
| 2 Nov | BE | Samarium (153Sm) Lexidronam Quadramet 1.3 GBq/ml inj. sol. i.v. vial 3.1 ml (4 GBq) | new shortage (back 15 Dec) |
Open shortages over time
Products short per day in the 5 countries tracked since 31 Oct 2026, from our daily snapshots. The history lengthens every day.
When its current shortages began
Against its peers
Breadth vs depth
Further right: more products short. Higher: more different medicines affected.
Medicines short
Download CSV| Medicine | Where this company is short | Products | Earliest start | Main reason | Short anywhere |
|---|---|---|---|---|---|
| Samarium (153Sm) Lexidronam | 3 | 19 Oct 2026 | Manufacturing problem | 3/16 |
Shortage data describes supply, not company finances. A shortage can mean lost sales for the supplier or extra demand for its competitors. Nothing here is investment advice; tickers are for identification only and may be out of date.